Wave Life Sciences (WVE) EBIAT (2016 - 2025)
Wave Life Sciences' EBIAT history spans 11 years, with the latest figure at -$53.2 million for Q4 2025.
- For Q4 2025, EBIAT fell 281.79% year-over-year to -$53.2 million; the TTM value through Dec 2025 reached -$204.4 million, down 110.68%, while the annual FY2025 figure was -$204.4 million, 110.68% down from the prior year.
- EBIAT reached -$53.2 million in Q4 2025 per WVE's latest filing, up from -$53.9 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of $29.3 million in Q4 2024 to a low of -$61.8 million in Q3 2024.
- Average EBIAT over 5 years is -$32.1 million, with a median of -$38.3 million recorded in 2021.
- The largest YoY upside for EBIAT was 279.95% in 2024 against a maximum downside of 951.9% in 2024.
- A 5-year view of EBIAT shows it stood at -$34.8 million in 2021, then decreased by 25.65% to -$43.7 million in 2022, then surged by 62.81% to -$16.3 million in 2023, then soared by 279.95% to $29.3 million in 2024, then plummeted by 281.79% to -$53.2 million in 2025.
- Per Business Quant, the three most recent readings for WVE's EBIAT are -$53.2 million (Q4 2025), -$53.9 million (Q3 2025), and -$50.5 million (Q2 2025).